Symbio Strengthens Leadership Team with New Executive Appointments

Date: January 13, 2025
Location: New York and Munster, Germany

In a proactive step towards bolstering its leadership structure, Symbio, the internationally recognized clinical research organization specializing in therapeutic solutions, has announced the appointment of two influential figures in its executive lineup. The appointments of Shanna Smith as Chief Commercial Officer (CCO) and Patrick Ronan as a member of its Board of Directors aim to accelerate Symbio’s growth trajectory and further enhance its commitment to delivering quality in clinical research.

Shanna Smith: A Veteran in Customer Solutions

Having dedicated 16 years to Symbio, Shanna Smith brings a wealth of experience in clinical operations and commercial services. In her new role as CCO, Smith is poised to optimize customer interactions and devise innovative solutions to meet evolving client needs. Her tenure at Symbio has been marked by significant contributions toward building robust relationships with both clients and investigators, which have propelled the organization’s expansion across global markets.

As CCO, Smith is expected to leverage her comprehensive understanding of the therapeutic landscape, ensuring that Symbio continues to meet the high expectations of its clients. Her strategic vision focuses on enhancing customer experiences and fostering long-term partnerships that drive mutual growth.

Patrick Ronan: A New Addition to the Board

Alongside Smith, Patrick Ronan has been appointed to the Board of Directors, bringing valuable expertise from his previous roles in life sciences. Currently serving as an Operating Partner at ARCHIMED, a global investment firm, Ronan has an impressive history as the CEO of Validant and Greenleaf Health, companies known for their impact in the healthcare sector. His experience also includes a notable tenure at Novartis, where he held the position of VP Regulatory Policy and External Affairs, plus a crucial role at the U.S. Food and Drug Administration (FDA) as Chief of Staff.

Ronan's addition to the Board is seen as a strategic move. His extensive background in regulatory affairs and operational management in the life sciences sector will significantly benefit Symbio as it continues to navigate the complexities of drug development and clinical trials.

Commitment to Excellence

In a joint statement, Alan Morgan, Chief Executive, and Nick Thornton, Chairman of Symbio, expressed their enthusiasm regarding these appointments: "The high caliber of these appointments reflects Symbio's commitment to bringing the highest levels of expertise to our clients' development programs. We congratulate Shanna and Patrick and wish them much success and enjoyment in their new roles."

About Symbio

Symbio stands apart as a global specialist in therapeutic clinical research, wielding significant expertise across various medical fields such as Dermatology, Aesthetics, Wound Care, Ophthalmology, Inflammation, and Gastroenterology. With operations spanning the United States and Europe, and supplemental expertise in Latin America and Asia, Symbio is dedicated to advancing therapeutic solutions through rigorous and effective clinical research.

As the organization ushers in this new phase, the leadership changes are reflective of Symbio's ongoing pursuit of excellence and commitment to addressing the dynamic needs of the healthcare landscape. With Smith and Ronan at the helm of its commercial and regulatory strategies, Symbio is well-positioned to continue its mission of enhancing patient outcomes globally.